Introduction
Patients with schizophrenia have a 15-to 20-year shorter life expectancy compared with the general population. 1 Previous research has shown a significant part of the increased mortality to be owed to cardiovascular diseases, including coronary artery disease. 2, 3 Possible explanations may be that patients with schizophrenia have an increased prevalence of cardiac risk factors, run a greater risk of experiencing an acute myocardial infarction (AMI) and are subsequently less likely to receive treatment in the form of coronary interventions. [3] [4] [5] [6] [7] [8] In addition, various antipsychotic treatments are known to cause adverse metabolic effects including insulin resistance, dyslipidaemia, and obesity, which are further risk factors for experiencing cardiac events. This study will investigate the effect of schizophrenia on major adverse cardiac events (MACE) defined as all-cause mortality, re-infarction, and stroke compared with a psychiatric healthy control (PHC) population. Moreover, length of hospital stays (LOS) and the prevalence of somatic comorbidities in patients with schizophrenia following acute coronary syndrome (ACS) will be analysed.
When compared with other studies in this area our study adds considerable new information in terms of specific outcomes and LOS. The Scandinavian perspective of this study provides results that are not influenced by the role of health insurance, since healthcare is equally available to all citizens of Denmark and the rest of Scandinavia. 10 
Methods

Study design
This nationwide register study includes patients with a first main diagnosis of ACS and a concurrent diagnosis of schizophrenia in Denmark in the period between 1 January 1995 and 31 December 2013.
Databases
All Danish residents are registered in the Danish Civil Registration System and assigned a unique 10-digit personal identification number.
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This number allows for linkage between national databases, including the Danish National Patient Register (NPR) and the Danish Psychiatric Central Register (DPCR). The NPR contains patient information from somatic wards at Danish hospitals since 1977. 12 The DPCR includes information on all psychiatric admissions from 1970, and following 1995 the DPCR has been integrated in the NPR. 13 
Study population
Initially all patients with a discharge diagnosis of ACS in Denmark were identified in the NPR using the World Health Organization's International Classification of Diseases 10th revision (ICD-10) diagnosis codes. The ACS diagnosis included unstable angina pectoris (I20.0), non-ST-segment elevation myocardial infarction (I21.4), ST-segment elevation myocardial infarction (I21.0-I21.3), and unspecified AMI (I21.9). These patients were then classified according to an additional diagnosis of narrow spectrum schizophrenia (ICD-10 F20, F25 and ICD-8 295) retrieved from the DPCR and NPR ignoring referring diagnoses. Narrow spectrum was chosen for greater diagnostic stability. 14 In this case, ICD-8 codes were used since the time of schizophrenia diagnosis could have predated the 10th revision. A second group of patients with no known psychiatric illness prior to incident ACS, referred to as PHC were defined as not being registered in the psychiatric part of NPR, the DPCR or have a diagnosis of psychiatric illness including intentional self-harm (ICD-10 F*, X60-X84, Y10-Y34 and ICD-8 290-315, E950-E959) in the somatic part of NPR.
Patients with any ACS diagnosis given prior to 1 January 1995 were excluded entirely. We also excluded incident patients diagnosed with ACS after 31 December 2013. Patients were followed until 31 December 2014, giving all patients at least 1 year of follow-up. Each patient with schizophrenia prior to incident ACS was matched to a PHC 1:2 on sex, date of birth (within 1 year), year of ACS diagnosis and risk score as defined below. Finally, we excluded unmatched subjects from further analysis.
Endpoints
The primary endpoint is a composite of MACE composed of all-cause mortality, re-infarction (ICD-10 I21.0-I21.4, I21.9), and stroke (ischaemic and haemorrhagic; ICD-10 I61, I63, I64, I69.3, and I69.4) following incident ACS. The secondary endpoints are the single endpoints of all-cause mortality, re-infarction, and stroke as well as the LOS and the development of incident coronary risk factors after index ACS event.
Risk score
The score measures degree of risk from confounding comorbidities prior to index. Moreover, the score is a three-level measure for which the first level indicates zero comorbidities, level two indicates up to two comorbidities, while level three indicates three or more comorbidities. The following comorbidities, each only counted once, were accounted for in confounding risk assessment:
• 
Length of hospital stay
The LOS following incident ACS was estimated as the total number of consecutive days spent in a hospital ward as acquired from the NPR taking into account possible transfers to different wards and/or hospitals.
Statistical analysis
Initially, we conducted descriptive quantification of the patients with schizophrenia calculating mean age at incident ACS and distribution of sex. In addition, we compared patients with schizophrenia to PHC on the risk factors used to define the risk score given above using the Fisher's exact test. For the primary endpoint, we employed Cox regression analysis and Kaplan-Meier analysis comparing the two matched populations. Similarly, Cox regression analyses were conducted for the secondary endpoints of all-cause mortality, re-infarction, and stroke. For re-infarction, we only accounted myocardial infarction (MI) following hospital discharge, hence, we used delayed-entry with entry being end of hospital stay. Nevertheless, we performed sensitivity analyses for MACE and reinfarction, for which we included diagnoses of infarct given during hospital stay. Likewise, we conducted additional sensitivity analyses for MACE, reinfarction, and stroke excluding patients who died during hospital stay. Sensitivity analyses were only conducted for the comparisons of the two matched populations. However, for all Cox regression analyses the origin was set at date of incident diagnosis of ACS and all subjects were followed until event, emigration, end of study or death, whichever came first. Furthermore, we compared the matched populations on LOS after index using Student's t-test. score given above as well as ACS following incident ACS. We employed Fisher's exact test for comparison, and used a time frame of maximum 1 year, 5 years, 10 years, and full follow-up period, respectively. A P-value less than 0.05 was considered statistically significant. All analyses were conducted using STATA version 14 (Stata corporation, College Station, TX, USA).
Results
Patient characteristics
This study consisted of 726 patients with schizophrenia matched 1:2 to 1452 PHC (total n = 2178), the baseline characteristics are shown in Table 1 . The study population consisted of 62% males and the mean age was 61 years. Patients with schizophrenia had higher prevalence of multiple comorbidities including diabetes, anaemia, heart failure, cardiomyopathy, chronic obstructive lung disease (COPD), and stroke. Moreover, we found lower prevalence's of hypertension and hyperlipidaemia (all P < 0.05). Table 2 displays the development of the different comorbidities 1 year, 5 years, and 10 years after index admission for ACS as well as for the full follow-up period following index admission until study end with a minimum follow-up of 1 year. Patients with schizophrenia had a decreased prevalence of hypertension, hyperlipidaemia and ACS in all four study periods. Furthermore, patients with schizophrenia had a higher prevalence of anemia, heart failure, cardiomyopathy, COPD, and PAD in one or more of the study periods.
Development of comorbidities
Major adverse cardiac events
Comparing the population with schizophrenia to the PHC population, we found the composite primary endpoint MACE to be increased by 62% [hazard ratio (HR) 1.62, 95% confidence interval (CI) 1.45-1.81; P < 0.001] as seen in Table 3 and Figure 1 . All-cause mortality (HR 2.54, 95% CI 2.22-2.90; P < 0.001) and stroke (HR 1.51, 95% CI 1.15-1.99; P = 0.003) as individual endpoints were also higher. There was no significant difference in re-infarction (HR 0.88, 95% CI 0.72-1.07; P = 0.2083). The sensitivity analyses on MACE and re-infarction excluding patients who died during the index hospitalization in which time of entry was set at study origin, showed a shift towards lower relative hazards with a HR for MACE of 1.17 (95% CI 1.06-1.29) and a HR for re-infarction of 0.80 (95% CI 0.70-0.91). Additional sensitivity analyses did not differ significantly from corresponding main analyses.
Length of hospital stay
We found no statistically significant difference in the LOS between the population with schizophrenia and the PHC population as seen in Table 4 .
Discussion
The findings in this study suggest that having schizophrenia when experiencing an ACS is associated with a higher risk of MACE, allcause mortality, and stroke compared with the PHC population.
However, we found no statistically significant effect of schizophrenia on the re-infarction rates and LOS following ACS.
We found patients with schizophrenia to have a lower prevalence of hypertension and hyperlipidaemia both at the time of admission and after index. These results are contradicting previous research that have concluded these patients to have higher rates of both hypertension and hyperlipidaemia. 15 This could perhaps be explained by underdiagnosing of these patients which could be correlated to the recurrent pattern of inferior treatment of somatic disease in patients with schizophrenia. The CATIE schizophrenia trial investigated the treatment in this population and found non-treatment rates at 62.4% for hypertension and 88.0% for hyperlipidaemia. 16 This undertreatment is also seen in Denmark during hospitalization for heart disease.
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Patients with schizophrenia in this study ran a greater risk of experiencing a stroke following discharge for an initial ACS. This is to our knowledge the first study that found this association. However, the fact that these patients run a greater risk of stroke, independent of ACS diagnosis, is previously known. 18 Two possible contributors to the increased risk of stroke following ACS are undertreatment and patient compliance, supported by our previous findings.
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The non-significant HRs for re-infarction may in part be explained by the high mortality in the population with schizophrenia resulting in a substantial competing risk of death. However, since our sensitivity analyses accounting death did not change our results significantly, another explanation could be that symptoms of a MI in patients with schizophrenia are not properly reported by the patient resulting in delayed hospital contact and ultimately premature death. 19, 20 With the current knowledge of increased morbidity and mortality in patients with schizophrenia, we expected to find a difference in the LOS between patients with schizophrenia and the PHC. A shorter LOS could have helped explain the increased mortality as a result of inferior treatment and a longer LOS could have helped explain the increased mortality as a result of the concurrent psychiatric diagnosis, which in turn might impede the treatment time. After correcting for death, we still found no difference in LOS and found a significant difference in MACE. This gives rise to the question of whether patients with schizophrenia should be offered a longer LOS in order to decrease subsequent MACE. A previous nationwide study from the US found that a 1-day decrease in LOS following MI with major complication increased the 30-day rehospitalization rate by 1.56 times. However, this was investigated in a general population and revealed no significant increase in rehospitalization when other comorbidities were corrected for. 21 There are a number of other studies analysing similar populations with schizophrenia in terms of LOS and outcomes following cardiovascular events. Protty et al. 22 published a population level study from the UK which showed a significant increase in LOS, in excess of what we report here. Similar outcomes were seen in terms of MACE and the individual components of MACE with a significant increase in all outcomes when corrected for baseline characteristics. There are a number of explanations as to why a significant increase in LOS is seen in this British population. Within the UK there is a significant lower provision of invasive coronary facilities and invasive procedures (per million of population) in terms of invasive consultant cardiologists, invasive cardiac catheter labs and the numbers and proportion of patients receiving invasive therapy after ischaemic cardiovascular events. 23 This environment is likely to lead to tighter selection of 24 This may go some way in explaining prolonged hospital stays whilst more complex patients are treated medically and stabilized. Guidelines based on a general population cannot be the determinant of LOS for patients with schizophrenia as these patients have a more complex medical history. Instead we suggest optimal specialized diagnostics and treatment in order to decrease the rates of MACE. It is difficult to say whether a longer LOS would serve as a solution to the increased morbidity and mortality seen in this study. However, it is important to provide these patients with as much social support as possible in the clinical settings, where the staff can influence the outcome. Hospitalization should provide the patient with a safety net and is an opportunity to educate the patient about possible complications and the benefit of lifestyle changes.
Limitations
Some limitations need to be taken into consideration. First, considering the long study period of almost two decades, data on only 726 patients with schizophrenia were available for analysis. An explanation could be that these patients might not have reached a hospital or received a diagnosis of ACS prior to their death, and are therefore, not included in the registry. Second, even though patients with schizophrenia were matched to PHC, residual confounding cannot be ruled out. Third, it is not possible to directly adjust for confounding due to lifestyle risk factors such as smoking status, since such are not recorded in the Danish national health registries. Hence, it is not possible to draw causal conclusions about differences in outcome. Lastly, the validity of a schizophrenia diagnosis in the Danish NPR has not been ascertained.
Conclusion
We found an association between schizophrenia and increased risk of MACE, all-cause mortality, and stroke following ACS despite a lower prevalence of diagnosed traditional cardiac risk factors such as hypertension and hyperlipidaemia. This may indicate that cardiac risk factors could be underdiagnosed in this population. Awareness of treatment bias and patient education may improve this increased risk, which future studies should address.
